December 03, 2013
1 min read

Visual acuity gain with anti-VEGF for pathologic myopia not maintained at 5 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

VIENNA — Five-year results of a study evaluating the safety and efficacy of bevacizumab in eyes with choroidal neovascularization secondary to pathologic myopia showed that the mean visual gain achieved at 2 years is not maintained.

“We should now investigate the prognostic factors as we did with AMD,” Paolo Lanzetta, MD, said at the Advanced Retinal Therapy meeting.

Phase 3 trials showed efficacy of Lucentis (ranibizumab, Novartis/Genentech) and Eylea (aflibercept, Bayer HealthCare/Regeneron) in inducing significant improvement in best corrected visual acuity over a shorter study duration.

“Bevacizumab is still an off-label drug,” Lanzetta said. “In our study, we included 100 eyes of 86 patients with subfoveal CNV lesions. All of them achieved 2 years of follow-up, and we have data on 32 eyes at 5 years.”

Patients received an average of 4.1 Avastin (bevacizumab, Roche/Genentech) treatments in 2 years and 6.7 in 5 years. While central retinal thickness had a progressive, stable decrease, the BCVA improvement of 0.13 logMAR at 2 years was down to 0.05 logMAR in the eyes seen at 5 years.

“The long-term prognosis is poor,” Lanzetta said.

The development of chorioretinal atrophy was investigated as a factor for poor outcomes.

“A significant +7.82 mm² increase in [chorioretinal atrophy] was found at 2 years and doubled in 18 patients at 5 years. No correlation was found with the number of intravitreal injections,” Lanzetta said.

The long-term implications of anti-VEGF therapy on chorioretinal atrophy, which is a major cause of visual loss in many cases, need to be clarified, he said.

Disclosure: Lanzetta is consultant to Bayer, Novartis and Roche.